Enterovirus A71 Vaccines

Enterovirus A71 (EV-A71) is a major causative agent of hand, foot, and mouth disease (HFMD) and herpangina. Moreover, EV-A71 infection can lead to neurological complications and death. Vaccination is the most efficient way to control virus infection. There are currently three inactivated, whole EV-A71 vaccines licensed by the China NMPA (National Medical Products Administration). Several other types of vaccines, such as virus-like particles and recombinant VP1 (capsid protein), are also under development. In this review, we discuss recent advances in the development of EV-A71 vaccines.

[1]  J. Mascola,et al.  Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination , 2020, The New England journal of medicine.

[2]  K. Yusoff,et al.  Recombinant Enterovirus 71 Viral Protein 1 Fused to a Truncated Newcastle Disease Virus NP (NPt) Carrier Protein , 2020, Vaccines.

[3]  R. Baric,et al.  Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults , 2020, The New England journal of medicine.

[4]  Javier Martin,et al.  WHO working group meeting to develop WHO Recommendations to assure the quality, safety and efficacy of enterovirus 71 vaccines , 2020, Vaccine.

[5]  Hai Yu,et al.  Recent Progress on the Versatility of Virus-Like Particles , 2020, Vaccines.

[6]  S. Shih,et al.  Enterovirus and Encephalitis , 2020, Frontiers in Microbiology.

[7]  Jen-Ren Wang,et al.  Enterovirus A71: virulence, antigenicity, and genetic evolution over the years , 2019, Journal of Biomedical Science.

[8]  Y. Poovorawan,et al.  The History of Enterovirus A71 Outbreaks and Molecular Epidemiology in the Asia-Pacific Region , 2019, Journal of Biomedical Science.

[9]  Yu-An Kung,et al.  Antivirals and vaccines for Enterovirus A71 , 2019, Journal of Biomedical Science.

[10]  S. Gau,et al.  Enterovirus A71 neurologic complications and long-term sequelae , 2019, Journal of Biomedical Science.

[11]  Jen-Ren Wang,et al.  Enterovirus A71 Containing Codon-Deoptimized VP1 and High-Fidelity Polymerase as Next-Generation Vaccine Candidate , 2019, Journal of Virology.

[12]  N. Chiu,et al.  Immunogenicity, safety, cross-reaction, and immune persistence of an inactivated enterovirus A71 vaccine in children aged from two months to 11 years in Taiwan. , 2019, Vaccine.

[13]  Quanyi Wang,et al.  Enterovirus A71 vaccine effectiveness in preventing enterovirus A71 infection among medically-attended hand, foot, and mouth disease cases, Beijing, China , 2019, Human vaccines & immunotherapeutics.

[14]  K. Wong,et al.  Development of live attenuated Enterovirus 71 vaccine strains that confer protection against lethal challenge in mice , 2019, Scientific Reports.

[15]  Kow-Tong Chen,et al.  Hand, foot and mouth disease and herpangina caused by enterovirus A71 infections: a review of enterovirus A71 molecular epidemiology, pathogenesis, and current vaccine development , 2018, Revista do Instituto de Medicina Tropical de Sao Paulo.

[16]  K. Fujii,et al.  VP1 Amino Acid Residue 145 of Enterovirus 71 Is a Key Residue for Its Receptor Attachment and Resistance to Neutralizing Antibody during Cynomolgus Monkey Infection , 2018, Journal of Virology.

[17]  Wei Zhang,et al.  A virus-like particle-based tetravalent vaccine for hand, foot, and mouth disease elicits broad and balanced protective immunity , 2018, Emerging Microbes & Infections.

[18]  Y. Chow,et al.  Mutations in VP1 and 5′-UTR affect enterovirus 71 virulence , 2018, Scientific Reports.

[19]  K. Chu,et al.  Five-year immunity persistence following immunization with inactivated enterovirus 71 type (EV71) vaccine in healthy children: A further observation , 2018, Human vaccines & immunotherapeutics.

[20]  K. Dong,et al.  Induction of a high-titered antibody response using HIV gag-EV71 VP1-based virus-like particles with the capacity to protect newborn mice challenged with a lethal dose of enterovirus 71 , 2018, Archives of Virology.

[21]  D. Weissman,et al.  mRNA vaccines — a new era in vaccinology , 2018, Nature Reviews Drug Discovery.

[22]  L. Lei,et al.  Hepatitis B virus core particles containing multiple epitopes confer protection against enterovirus 71 and coxsackievirus A16 infection in mice. , 2017, Vaccine.

[23]  E. Nikonova,et al.  Enteroviruses: Classification, diseases they cause, and approaches to development of antiviral drugs , 2017, Biochemistry (Moscow).

[24]  Yongge Wu,et al.  Characterization of human enterovirus71 virus-like particles used for vaccine antigens , 2017, PloS one.

[25]  Y. Choi,et al.  An inactivated hand-foot-and-mouth disease vaccine using the enterovirus 71 (C4a) strain isolated from a Korean patient induces a strong immunogenic response in mice , 2017, PloS one.

[26]  I. Sam,et al.  Immunodominant IgM and IgG Epitopes Recognized by Antibodies Induced in Enterovirus A71-Associated Hand, Foot and Mouth Disease Patients , 2016, PloS one.

[27]  Kyung Yeon Lee,et al.  Enterovirus 71 infection and neurological complications , 2016, Korean journal of pediatrics.

[28]  Longyun Chen,et al.  Vesicular stomatitis virus-based vaccines expressing EV71 virus-like particles elicit strong immune responses and protect newborn mice from lethal challenges. , 2016, Vaccine.

[29]  Jing-xin Li,et al.  Enterovirus 71: a whole virion inactivated enterovirus 71 vaccine , 2016, Expert review of vaccines.

[30]  Zhenglun Liang,et al.  EV71 vaccine, a new tool to control outbreaks of hand, foot and mouth disease (HFMD) , 2016, Expert review of vaccines.

[31]  W. Kong,et al.  A new EV71 VP3 epitope in norovirus P particle vector displays neutralizing activity and protection in vivo in mice. , 2015, Vaccine.

[32]  N. Packer,et al.  Modification of Asparagine-Linked Glycan Density for the Design of Hepatitis B Virus Virus-Like Particles with Enhanced Immunogenicity , 2015, Journal of Virology.

[33]  Chao Zhang,et al.  High-yield production of recombinant virus-like particles of enterovirus 71 in Pichia pastoris and their protective efficacy against oral viral challenge in mice. , 2015, Vaccine.

[34]  N. Silverberg,et al.  Update on hand-foot-and-mouth disease. , 2015, Clinics in dermatology.

[35]  P. Chong,et al.  Review of enterovirus 71 vaccines. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[36]  Q. Jin,et al.  Characterization of the enterovirus 71 VP1 protein as a vaccine candidate , 2015, Journal of medical virology.

[37]  Chuan-Tien Hung,et al.  Update on the development of enterovirus 71 vaccines , 2014, Expert opinion on biological therapy.

[38]  Q. Jin,et al.  Characterization of the enterovirus 71 P1 polyprotein expressed in Pichia pastor as a candidate vaccine , 2014, Human vaccines & immunotherapeutics.

[39]  J. Kwang,et al.  Attenuation of Human Enterovirus 71 High-Replication-Fidelity Variants in AG129 Mice , 2014, Journal of Virology.

[40]  Jiansheng Liu,et al.  An inactivated enterovirus 71 vaccine in healthy children. , 2014, The New England journal of medicine.

[41]  Wenbo Xu,et al.  Efficacy, safety, and immunogenicity of an enterovirus 71 vaccine in China. , 2014, The New England journal of medicine.

[42]  Qinjian Zhao,et al.  Protection against Lethal Enterovirus 71 Challenge in Mice by a Recombinant Vaccine Candidate Containing a Broadly Cross-Neutralizing Epitope within the VP2 EF Loop , 2014, Theranostics.

[43]  Jen-Ren Wang,et al.  Formalin-Inactivated EV71 Vaccine Candidate Induced Cross-Neutralizing Antibody against Subgenotypes B1, B4, B5 and C4A in Adult Volunteers , 2013, PloS one.

[44]  C. Qin,et al.  Virus-like particles for enterovirus 71 produced from Saccharomyces cerevisiae potently elicits protective immune responses in mice. , 2013, Vaccine.

[45]  Hyunwook Lee,et al.  Enterovirus 71 Binding to PSGL-1 on Leukocytes: VP1-145 Acts as a Molecular Switch to Control Receptor Interaction , 2013, PLoS pathogens.

[46]  Pei Liu,et al.  Efficacy, safety, and immunology of an inactivated alum-adjuvant enterovirus 71 vaccine in children in China: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial , 2013, The Lancet.

[47]  Yi-Tsung Lin,et al.  A Phase I, randomized, open-label study to evaluate the safety and immunogenicity of an enterovirus 71 vaccine. , 2013, Vaccine.

[48]  P. McMinn,et al.  Ribavirin-Resistant Mutants of Human Enterovirus 71 Express a High Replication Fidelity Phenotype during Growth in Cell Culture , 2012, Journal of Virology.

[49]  Min-Shi Lee,et al.  Pilot Scale Production of Highly Efficacious and Stable Enterovirus 71 Vaccine Candidates , 2012, PloS one.

[50]  Yu-Chen Hu,et al.  Enterovirus type 71 neutralizing antibodies in the serum of macaque monkeys immunized with EV71 virus-like particles. , 2012, Vaccine.

[51]  Gwyndaf Evans,et al.  A sensor-adaptor mechanism for enterovirus uncoating from structures of EV71 , 2012, Nature Structural &Molecular Biology.

[52]  P. Chong,et al.  Selection and characterization of vaccine strain for Enterovirus 71 vaccine development. , 2012, Vaccine.

[53]  Junzhi Wang,et al.  Establishing China's national standards of antigen content and neutralizing antibody responses for evaluation of enterovirus 71 (EV71) vaccines. , 2011, Vaccine.

[54]  Jen-Ren Wang,et al.  A Single Nucleotide in Stem Loop II of 5′-Untranslated Region Contributes to Virulence of Enterovirus 71 in Mice , 2011, PloS one.

[55]  Hongling Zhao,et al.  Immunoprotection elicited by an enterovirus type 71 experimental inactivated vaccine in mice and rhesus monkeys. , 2011, Vaccine.

[56]  J. Kwang,et al.  Display of VP1 on the Surface of Baculovirus and Its Immunogenicity against Heterologous Human Enterovirus 71 Strains in Mice , 2011, PloS one.

[57]  V. Stollar,et al.  Host Factors in Enterovirus 71 Replication , 2011, Journal of Virology.

[58]  P. Phuektes,et al.  Formalin-inactivated vaccine provokes cross-protective immunity in a mouse model of human enterovirus 71 infection. , 2011, Vaccine.

[59]  Yongqiang Deng,et al.  Antibody dependent enhancement infection of Enterovirus 71 in vitro and in vivo , 2011, Virology Journal.

[60]  T. Solomon,et al.  Clinical features, diagnosis, and management of enterovirus 71 , 2010, The Lancet Neurology.

[61]  Lianfeng Zhang,et al.  Combined peptides of human enterovirus 71 protect against virus infection in mice. , 2010, Vaccine.

[62]  V. Chow,et al.  Passive protection against lethal enterovirus 71 infection in newborn mice by neutralizing antibodies elicited by a synthetic peptide. , 2007, Microbes and infection.

[63]  T. Wakita,et al.  An Attenuated Strain of Enterovirus 71 Belonging to Genotype A Showed a Broad Spectrum of Antigenicity with Attenuated Neurovirulence in Cynomolgus Monkeys , 2007, Journal of Virology.

[64]  V. Chow,et al.  Identification of neutralizing linear epitopes from the VP1 capsid protein of Enterovirus 71 using synthetic peptides. , 2007, Virus research.

[65]  M. Ho,et al.  Expression, purification and characterization of enterovirus-71 virus-like particles. , 2006, World journal of gastroenterology.

[66]  P. Minor,et al.  Polio eradication, cessation of vaccination and re-emergence of disease , 2004, Nature Reviews Microbiology.

[67]  J. Hsu,et al.  Formation of enterovirus-like particle aggregates by recombinant baculoviruses co-expressing P1 and 3CD in insect cells , 2003, Biotechnology Letters.

[68]  D. Montefiori,et al.  Modifications of the Human Immunodeficiency Virus Envelope Glycoprotein Enhance Immunogenicity for Genetic Immunization , 2002, Journal of Virology.

[69]  C. Wychowski,et al.  Induction of Hepatitis C Virus E1 Envelope Protein-Specific Immune Response Can Be Enhanced by Mutation of N-Glycosylation Sites , 2001, Journal of Virology.

[70]  M. Ho,et al.  Protection against lethal enterovirus 71 infection in newborn mice by passive immunization with subunit VP1 vaccines and inactivated virus. , 2001, Vaccine.

[71]  R. Dwek,et al.  Glycosylation and the immune system. , 2001, Science.

[72]  M. Pallansch,et al.  Enterovirus 71 infections and neurologic disease--United States, 1977-1991. , 1994, The Journal of infectious diseases.

[73]  K. Chu,et al.  2-Year Efficacy, Immunogenicity, and Safety of Vigoo Enterovirus 71 Vaccine in Healthy Chinese Children: A Randomized Open-Label Study , 2017, The Journal of infectious diseases.